MedCity News
MAY 20, 2024
A good outsourced partner can work alongside in-house accountants and stay on top of the moving target of healthcare accounting regulations, addressing tax risks and identifying cost-saving opportunities. The post Tax Challenges for Healthcare Accounting Teams Bring Opportunity for Innovation appeared first on MedCity News.
PharmaVoice
MAY 20, 2024
The “Nobel Prize-worthy invention” could be worth hundreds of billions commercially — and have a deep impact on drug R&D.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
MAY 20, 2024
The Singapore manufacturing site will be AstraZeneca’s first facility capable of handling all steps of antibody drug conjugate production. AstraZeneca aims to open the facility in 2029. The post AstraZeneca Plans $1.5B Manufacturing Site for Global Production of ADC Cancer Drugs appeared first on MedCity News.
Fierce Pharma
MAY 20, 2024
A Delaware federal jury has ordered AstraZeneca to fork over $107.5 million to Pfizer for infringing two of the latter company's patents with its marketing of blockbuster oncology med Tagrisso. | Pfizer's Wyeth subsidiary and licensee Puma Biotechnology sued AstraZeneca in 2021 for alleged patent infringement related to AZ's marketing of cancer blockbuster Tagrisso.
Advertiser: ZoomInfo
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
MedCity News
MAY 20, 2024
Fay emerged from stealth with $25 million in funding. The company connects patients to a network of registered dietitians. The post Nutrition Counseling Startup Emerges from Stealth with $25M appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
MAY 20, 2024
Centivo, a health plan that sells to self-funded employers, acquired virtual-first primary care startup Eden Health. With this acquisition, Centivo now serves more than 160 employers in all 50 states. The post Centivo Acquires a Primary Care Startup, Despite Others Fleeing the Space appeared first on MedCity News.
Fierce Pharma
MAY 20, 2024
Even as GSK defends itself against thousands of personal injury lawsuits relating to its sale of heartburn pill Zantac, a whistleblower lawsuit from the laboratory that first raised alarm bell | A newly unsealed complaint from the laboratory that first revealed Zantac's links to a carcinogenic impurity lays out a web of allegations about GSK's efforts to bring the drug to market in the 1980s and its attempts to hide the risks since then.
MedCity News
MAY 20, 2024
The PTC Therapeutics drug Translarna failed its confirmatory study in Duchenne muscular dystrophy. Analysts say the European Commission’s decision to not adopt the Committee on Medicinal Products for Human Use’s negative opinion on the drug is unusual, if not unprecedented. The post European Commission Decision Is a Reprieve for PTC Therapeutics’ Rare Muscle Disease Drug appeared first on MedCity News.
Fierce Pharma
MAY 20, 2024
At the American Thoracic Society international conference in San Diego, one of the major themes is the advance of new therapies for chronic obstructive pulmonary disease (COPD). | At the American Thoracic Society international conference, one of the major themes is the advance of new therapies for COPD. On Monday, Sanofi and Regeneron had their answer to Amgen and AstraZeneca's presentation from the day before.
Speaker: Jesse Hunter and Brynn Chadwick
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
MedCity News
MAY 20, 2024
Dan Reedy, senior director of pricing and underwriting for Abarca, spoke recently with MedCity News about what payers should consider as they explore new models and press for greater transparency. The post Unlocking Transparency in PBM Pricing appeared first on MedCity News.
Fierce Pharma
MAY 20, 2024
Riding high on its Daiichi Sankyo-partnered antibody drug conjugate (ADC) Enhertu—and banking on an approval for its next ADC contender datopotamab durextecan this winter—AstraZeneca is placing a b | Riding high on its Daiichi Sankyo-partnered antibody drug conjugate (ADC) Enhertu—and banking on an approval for its next ADC contender datopotamab durextecan this winter—AstraZeneca is placing a big bet on the cancer-fighting technology as it blueprints a massive manufacturing investment in Asia.
PharmaVoice
MAY 20, 2024
How persistence led to BioLineRx’s first approved therapy and promising pipeline.
Fierce Pharma
MAY 20, 2024
Four months after Europe's drug reviewers doubled down and recommended the withdrawal of PTC Therapeutics' Translarna for lack of efficacy, the drug's regulatory odyssey is taking yet another | Two negative recommendations from the Committee for Medicinal Products for Human Use were not enough to convince the European Commission that Translarna should be removed from the market.
Advertiser: ZoomInfo
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
Pharmaceutical Technology
MAY 20, 2024
Nearly 30,000 people, including children in clinical trials, were infected with hepatitis C and HIV from contaminated blood products in the 1970s and 1980s.
Fierce Pharma
MAY 20, 2024
Sanofi and Regeneron’s Dupixent appears set up for a key FDA approval this summer for chronic obstructive pulmonary disorder (COPD). | Sanofi and Regeneron’s Dupixent appears set up for a key FDA approval this summer for chronic obstructive pulmonary disorder (COPD). But a second biologic treatment could be on its heels in the indication. Amgen and AstraZeneca have reported data that did not meet the primary endpoint of a phase 2a trial but did show the effectiveness of their asthma drug Tezspir
PharmaVoice
MAY 20, 2024
Planning early, staying nimble and approaching commercialization as a team sport should be top priorities, the leaders said.
PharmaTimes
MAY 20, 2024
Both drugs have the potential to offer a disease-modifying approach to the lung disease
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
pharmaphorum
MAY 20, 2024
Amgen and AstraZeneca have said their severe asthma therapy Tezspire could have a role to play in chronic obstructive pulmonary disease (COPD) – a key target indication for the drug – despite missing its primary objective in a clinical trial.
PharmaTimes
MAY 20, 2024
Globally affecting 4% of the population, autoimmune diseases mistakenly attack healthy cells, tissues and organs in the body
pharmaphorum
MAY 20, 2024
Phase 2a data with drugs for idiopathic pulmonary fibrosis from Vicore and Endeavor raise hopes of disease-modifying therapy for the disease
Pharmaceutical Commerce
MAY 20, 2024
The facility, company says, will be its first that covers end-to-end ADC production.
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
pharmaphorum
MAY 20, 2024
Biotechs Rapport and Telix throw their hats into IPO ring Phil.
Pharmaceutical Commerce
MAY 20, 2024
The latest news for pharma industry insiders.
European Pharmaceutical Review
MAY 20, 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) new Notification Scheme for lower-risk clinical trials has enabled an application for a Phase IV haemophilia A clinical trial to be accepted by day 14. approximately 20 percent of UK initial clinical trial applications are anticipated to be eligible [for the MHRA’s new Notification Scheme]” The treatment, Nuwiq, is a fourth-generation recombinant FVIII is indicated for severe haemophilia A in patients undergoing major sur
PharmaTech
MAY 20, 2024
The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
European Pharmaceutical Review
MAY 20, 2024
A new $1.5 billion antibody drug conjugate (ADC) manufacturing facility in Singapore is set to increase global supply of AstraZeneca’s ADC portfolio. More about the ADC facility The planned greenfield facility will be the company’s first end-to-end ADC production site” The planned greenfield facility will be the company’s first end-to-end antibody drug conjugate production site.
Pharmaceutical Technology
MAY 20, 2024
A recent study in England has shown that the HPV vaccine in teenagers reduced the rate of cervical cancer by up to 85%.
pharmaphorum
MAY 20, 2024
AstraZeneca is backing up its big investments in antibody-drug conjugates (ADCs) with the construction of a $1.5bn new facility in Singapore.
Expert insights. Personalized for you.
325 
Let's personalize your content